{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:53:39Z","timestamp":1787928819465,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2138"],"award-info":[{"award-number":["JPMJSP2138"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04223"],"award-info":[{"award-number":["21H04223"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116801","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:02:43Z","timestamp":1716397363000},"page":"116801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia"],"prefix":"10.1016","volume":"175","author":[{"given":"Danni","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9571","authenticated-orcid":false,"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9775-3779","authenticated-orcid":false,"given":"Fumihiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.biopha.2024.116801_bib1","article-title":"Linezolid in vitro: mechanism and antibacterial spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2024.116801_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2024.116801_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","article-title":"Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy","volume":"73","author":"Chen","year":"2012","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"1","key":"10.1016\/j.biopha.2024.116801_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2024.116801_bib5","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2024.116801_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00027-20","article-title":"Accumulation of major linezolid metabolites in patients with renal impairment","volume":"64","author":"Souza","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.biopha.2024.116801_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.biopha.2024.116801_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.xphs.2020.09.004","article-title":"Drug metabolites potently inhibit renal organic anion transporters, OAT1 and OAT3","volume":"110","author":"Zou","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2024.116801_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/jps.23433","article-title":"Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure","volume":"102","author":"Komazawa","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2024.116801_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","article-title":"Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy","volume":"17","author":"Takahashi","year":"2011","journal-title":"J. Infect. Chemother."},{"issue":"12","key":"10.1016\/j.biopha.2024.116801_bib11","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1124\/dmd.114.058529","article-title":"Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3","volume":"42","author":"Chioukh","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.biopha.2024.116801_bib12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.116.070722","article-title":"Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral human organic anion transporter 3","volume":"44","author":"Ikemura","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.biopha.2024.116801_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"10.1016\/j.biopha.2024.116801_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-4827(91)90560-H","article-title":"Production of platelet-like particles by a human megakaryoblastic leukemia cell line (MEG-01)","volume":"193","author":"Takeuchi","year":"1991","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116801_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1039\/b100076o","article-title":"Determination of linezolid in human plasma by LC-MS-MS","volume":"126","author":"Phillips","year":"2001","journal-title":"Analyst"},{"issue":"3","key":"10.1016\/j.biopha.2024.116801_bib16","first-page":"407","article-title":"Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days","volume":"82","author":"Sato","year":"2020","journal-title":"Nagoya J. Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116801_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"3-4","key":"10.1016\/j.biopha.2024.116801_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000485920","article-title":"Stereoselective inhibition of renal basolateral human organic anion transporter 3 by lansoprazole enantiomers","volume":"101","author":"Hamada","year":"2018","journal-title":"Pharmacology"},{"issue":"10","key":"10.1016\/j.biopha.2024.116801_bib19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/00498250210158249","article-title":"Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog","volume":"32","author":"Slatter","year":"2002","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.biopha.2024.116801_bib20","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1248\/bpb.b16-00427","article-title":"Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2","volume":"39","author":"Tajima","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"8","key":"10.1016\/j.biopha.2024.116801_bib21","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:44:33Z","timestamp":1741031073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":21,"alternative-id":["S0753332224006851"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116801","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116801"}}